Strategies for optimizing the development of your inhaled pharmaceutical product when moving from nonclinical to first-in-human studies

Incorporating an inhalation device in your drug development creates greater complexity in dose administration, enhancing the need for knowledge sharing and collaboration across drug development teams between nonclinical and first-in-human (FIH) studies. Connecting insights between development phases improves the scientific integrity, efficiency, speed and patient safety of the transition and ultimately expedites delivery of new inhaled medications into the hands of patients-where they are needed most.